Fed up with flakes on your shoulders and an itchy scalp that just won't settle? Before you buy yet another shampoo, here's ...

Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

Alumis' Phase 3 ONWARD data show envudeucitinib delivers durable scalp clearance and itch relief through 48 weeks in ...

A national analysis of US ambulatory care visits finds patients with psoriasis have more than eightfold increased odds of ...

A two-year Japanese real-world study of 66 patients shows the dual IL-17A and IL-17F inhibitor bimekizumab sustained high ...

Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...

Zasocitinib demonstrated superiority over deucravacitinib for the treatment of moderate to severe plaque psoriasis, according ...

These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth ...

Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.

New data from an Eli Lilly study found that adults with moderate-to-severe psoriasis and obesity experienced broader immune ...

Combining Taltz and Zepbound improves psoriasis symptoms and metabolic biomarkers in patients with obesity.

Dr. Bunick introduces the panel's second case: a 72-year-old retired school administrator with plaque psoriasis diagnosed at ...